News >

CAR T-Cell Therapy an Emerging Explosion in Myeloma Paradigm

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 23, 2018

Nina Shah, MD

Nina Shah, MD
Recent dose-escalation findings in chimeric antigen receptor (CAR) T-cell therapy presented at the 2017 ASH Annual Meeting continue to show high potential in heavily pretreated patients with multiple myeloma.

on Hematologic Malignancies.

OncLive: You lectured on immunotherapy and novel agents for refractory myeloma. What developments have we been seeing?

Shah: This is a really exciting field because there are multiple areas where there have been a lot of developments. We talked about the major categories of immunotherapy, including antibody therapy, cellular therapy, and some of the novel twists on antibodies, including antibody-drug conjugates, as well as bispecific antibodies. We talked about the updated elotuzumab (Empliciti) data, as well as that of daratumumab (Darzalex). Both of these have held onto their PFS benefit that they showed in the initial studies. That is exciting because a lot of patients are able to get these therapies sooner in their relapse course and for longer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x